Recommendations for counseling persons infected with human T-lymphotrophic virus, types I and II = Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus
Published Date:June 25, 1993
Corporate Authors:Centers for Disease Control and Prevention (U.S.) ; U.S. Public Health Service Working Group for Recommendations for Counseling Persons Infected with Human T-Lymphotropic Virus, Types I and II. ; U.S. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. ; ... More ▼
Keywords:AIDS-Related Opportunistic Infections/prevention & Control
Anti-Bacterial Agents/therapeutic Use
HTLV-II Infections/prevention & Control
HTLV-I Infections/prevention & Control
Mycobacterium Avium-intracellulare Infection/complications
Mycobacterium Avium-intracellulare Infection/prevention & Control
Patient Education As Topic
Series:MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 42, no. RR-9
Description:Recommendations for counseling persons infected with human T-lymphotrophic virus, types I and II: The human T-lymphotropic viruses, type I (HTLV-I) and type II (HTLV-II), are closely related but distinct retroviruses that can infect humans. They are different from the human immunodeficiency viruses that cause acquired immunodeficiency syndrome. Screening of the U.S. blood supply for HTLV-I/II, which began in 1988, identifies HTLV-I- and HTLV-II-infected persons who should be counseled regarding their infections. This document summarizes current information about HTLV, types I and II, and presents recommendations developed by CDC and a U.S. Public Health Service working group for counseling HTLV-I- and HTLV-II-infected persons.
Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus: Mycobacterium avium complex (MAC) causes disseminated disease in up to 40% of patients with advanced human immunodeficiency virus (HIV) disease in the United States. A U.S. Public Health Service Task Force convened to address the prophylaxis and therapy of MAC recommends that patients with HIV infection and <100 CD4+ T-lymphocytes/mL be administered prophylaxis against MAC. The recommended regimen is rifabutin, 300 mg by mouth daily, for the patient’s lifetime. If disseminated MAC develops, a treatment regimen containing clarithromycin or azithromycin and at least one other agent is recommended. Diagnosis, therapy, and prophylaxis for HIV-infected children follow similar guidelines.
Supporting Files:No Additional Files
You May Also Like: